Compact USB-C interface for connecting a Morse straight key or iambic paddle to phones and computers. The project starts with an Adafruit KB2040 breadboard prototype and is intended to progress to a ...

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today ...

Iambic Therapeutics just found out what public investors think of an AI-powered cancer drug developer. The answer, at least on day one, was enthusiastic. The San Diego biotech’s shares rose 16% to $18 ...

Iambic Therapeutics, a startup using artificial intelligence to find new medicines, said Wednesday it raised $150 million in an initial public offering. The startup sold close to 9.4 million shares at ...

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800 million if all goes through as planned. The NVIDIA-backed ...

Clinical-stage cancer drug and tech firm Iambic Therapeutics raised $150 million in its U.S. IPO, then surged about 18% on day one. Shares finished Thursday at $18.91 versus a $16 offer price, ...

Iambic Therapeutics (IAM), a life sciences company backed by Nvidia (NVDA) and AbbVie (ABBV), among others, on Thursday detailed its plans to go public at a valuation exceeding $800M through a Nasdaq ...

Iambic Therapeutics, Inc. (Iambic), a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced the submission of an Investigational ...